Ozmosi | Phendimetrazine Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Phendimetrazine

Alternative Names: phendimetrazine, sprx-105, melfiat-105, bontril, phenazine, x-trozine l.a., sprx-3, cam-metrazine, adphen, alphazine, x-trozine, phenazine-35, plegine, metra, statobex, di-metrex, melfiat, statobex-g, bontril pdm, fendique er
Clinical Status: Inactive
Latest Update: 2026-02-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADRA1A Agonist, ADRA1B Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Approved

Approved Countries: Bangladesh | India | Italy | Korea | Pakistan | United States

Approved Indications: None

Known Adverse Events: None

Company: eGenesis, INC
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Phendimetrazine

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Acute-On-Chronic Liver Failure|Hepatic Encephalopathy|Liver Failure, Acute

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT07429838

EGEN-5784-CL-1001

P1

Not yet recruiting

Liver Failure, Acute|Hepatic Encephalopathy|Acute-On-Chronic Liver Failure

2027-12-15

50%

2026-02-25